Skip to main content

Advertisement

SpringerLink
Log in

Does comorbidity affect the benefit of intensive glycemic control in older patients with type 2 diabetes mellitus?

  • Practice Point
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

Abstract

This Practice Point commentary discusses a computer-based decision analysis by Huang et al. that assessed the effect of comorbid illnesses and functional status on the benefits of intensive glycemic control (HbA1c 7.0%) in hypothetical older patients with type 2 diabetes mellitus (T2DM). The expected benefits of intensive glycemic control ranged from 51–116 additional days of quality-adjusted life expectancy (quality-adjusted days). Expected benefits decreased with increasing age or number of comorbidities, and increased with duration of T2DM. We highlight the issues to consider in the extrapolation of theoretical models to the clinical setting. In the examined study, the input data were several decades old, interpretation of the mean quality-adjusted days gained lacked comparative benchmarks, and a 'survivor effect' probably accounted for the increased benefit associated with an increased duration of T2DM. Nevertheless, the data do suggest that the benefits of intensive control might be diminished in older patients with multiple comorbidities and functional impairments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Huang ES et al. (2008) The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med 149: 11–19

    Article  Google Scholar 

  2. Eastman RC et al. (1997) Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 20: 725–734

    Article  CAS  Google Scholar 

  3. Klein R and Moss S (1995) A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 155: 745–754

    Article  CAS  Google Scholar 

  4. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853

  5. Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545–2559

  6. American Diabetes Association et al. (2008) Standards of medical care in diabetes—2008. Diabetes Care 31 (Suppl 1): S12–S54

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Department of Medicine, CD Saudek is Hugh P McCormick Family Professor of Endocrinology and Metabolism at John Hopkins University School of Medicine and Director of the Johns Hopkins Diabetes Center; RR Kalyani is Senior Clinical and Research Fellow, John Hopkins University School of Medicine, Baltimore, MD, USA.,

    Christopher D Saudek & Rita R Kalyani

  2. RR Kalyani is Senior Clinical and Research Fellow, Division of Endocrinology and Metabolism, Department of Medicine, John Hopkins University School of Medicine, Baltimore, MD, USA.,

    Christopher D Saudek & Rita R Kalyani

Authors
  1. Christopher D Saudek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rita R Kalyani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher D Saudek.

Ethics declarations

Competing interests

Christopher D Saudek declared associations with the following companies: GlaxoSmithKline, Novartis and Pfizer (reports consulting or medical advisory board participation). Rita R Kalyani declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saudek, C., Kalyani, R. Does comorbidity affect the benefit of intensive glycemic control in older patients with type 2 diabetes mellitus?. Nat Rev Endocrinol 5, 78–79 (2009). https://doi.org/10.1038/ncpendmet1041

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet1041

  • Springer Nature Limited

Search

Navigation